Narayana Health moves into UK market with PPG acquisition
India-based healthcare provider Narayana Health’s £183 million acquisition of UK-based Practice Plus Group (PPG) Hospitals Limited marks a transformative entry into Europe’s largest healthcare market.
Novartis acquires biopharmaceutical group Avidity for $12bn
Global pharmaceutical and healthcare company Novartis has agreed to acquire biopharmaceutical company Avidity Biosciences for around $12 billion . The transaction is expected to close in the first half of 2026 and follows Avidity’s separation of its early-stage precision cardiology programs into a new publicly traded entity SpinCo. The move significantly strengthens Novartis’ neuroscience franchise by adding three late-stage neuromuscular…
Welltower invests £6.4bn in UK senior care homes
US-based REIT Welltower has invested a total of £6.4bn in UK senior care homes operated by HC-One and Barchester Healthcare. Candesic supported Welltower in part of this process looking at select assets. The largest component of the transaction is the acquisition of a real estate portfolio of Barchester-operated communities for £5.2 billion. As part of the transaction, Welltower has formed an exclusive…
Alcon broadens Vision Care Portfolio with $1.5bn Acquisition of STAAR Surgical
Swiss-American pharmaceutical and medical device company Alcon has struck a definitive agreement to purchase STAAR Surgical in a deal which values the phakic IOL specialist at roughly $1.5 billion, but the shareholder vote on the takeover offer has been delayed until November 6.
Blackstone and TPG acquiring Hologic in $18.3bn take-private deal
American Medtech company Hologic Inc. has agreed to be acquired by private equity giants Blackstone and TPG in a landmark $18.3 billion enterprise value deal, marking one of the largest healthcare take-private transactions of 2025. The agreement to buy Hologic – which specialises in women’s health diagnostics, including breast and cervical cancer screening – will see it delisted from the Nasdaq stock market. It delivers immediate value to shareholders…
Novo Nordisk acquiring Akero Therapeutics for $5.2bn
Denmark-based global pharma company Novo Nordisk is to acquire clinical stage company Akero Therapeutics for up to $5.2bn, filling a critical comorbidity gap within Novo Nordisk’s core therapeutic landscape. The deal adds potential first-in-class MASH (Metabolic Dysfunction-Associated Steatohepatitis, a severe form of fatty liver disease) therapy. This is Novo Nordisk’s largest R&D-focused acquisition to date, strategically aligning with its core…
Genmab broadens late-stage portfolio with $8bn Merus acquisition
Copenhagen-based antibody therapeutics company Genmab has agreed to acquire Merus in a deal valuing the Dutch–U.S. oncology company at approximately $8bn. The move brings late-stage bispecific antibody petosemtamab into Genmab’s pipeline. Petosemtamab is in two Phase 3 trials for head and neck cancer, carries two FDA Breakthrough Therapy Designations, and could launch as early as 2027. According to Alcon’s management,…
Roche Expands Metabolic Portfolio with US$3.5bn acquisition of 89bio
Swiss multinational pharma and diagnostics giant Roche has signed a definitive agreement to acquire California-based biotech group 89bio in a deal worth up to US$3.5bn, planning to expand in cardiovascular, renal and metabolic diseases while diversifying beyond oncology and immunology. Roche will pay US$2.4bn upfront, and up to US$3.5bn if certain milestones are hit tied to commercial success / annual sales targets.…
Fresenius Medical Care acquires kidney specialist Interwell Health
The world’s leading provider of products and services for people with chronic kidney failure, Fresenius Medical Care, has finalised its full acquisition of all non-physician stakes in the U.S.-based kidney care and support group Interwell Health (IWH) for €312m. The transaction strengthens Fresenius’ position as the undisputed leader in renal value-based care, uniquely combining nephrologist networks, clinic infrastructure, and proprietary health…
GTCR Acquires Zentiva from Advent in $4.8bn Deal
Global private equity firm Advent International has agreed to sell Czech generics leader Zentiva to Chicago-based private equity firm GTCR for €4.1bn, marking one of Europe’s largest healthcare transactions of 2025 and underscoring robust investor appetite for stable pharmaceutical assets. Advent acquired Zentiva from Sanofi in 2018 for €1.9bn and exits at more than double the valuation, reflecting seven years of operational transformation. Under Advent, Zentiva doubled…